Development of a broad-based ADME panel for use in pharmacogenomic studies

Pharmacogenomics

Volumn 15, Issue 9, 2014, Pages 1185-1195

  Brown, Andrew M K ^a,b,c   Renaud, Yannick ^a,b   Ross, Colin ^d,e   Hansen, Mark ^f   Mongrain, Ian ^a,b   Valois, Diane ^a,b   Carleton, Bruce C ^d,g   Hayden, Michael R ^d   Dubé, Marie Pierre ^a,b   Tardif, Jean Claude ^a,b   Phillips, Michael S ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f ILLUMINA INC   (United States)

^g BC CHILDREN S HOSPITAL   (Canada)

Author keywords

ADME; drug metabolism; genotyping; pharmacogenomics; SNPs

Indexed keywords

ADME PANEL; ALLELE; ARTICLE; BINDING AFFINITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HAPLOTYPE MAP; HUMAN; PHARMACOGENOMICS; PROCESS DESIGN; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION STUDY; CLINICAL TRIAL (TOPIC); GENOTYPE; METABOLISM; PHARMACOGENETICS; PHARMACOKINETICS; PROCEDURES;

DRUG;

CLINICAL TRIALS AS TOPIC; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84906533636     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.81     Document Type: Article

References (32)

1. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol. Med. 7(5), 201-204 (2001).
2. Wilkinson GR. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352(21), 2211-2221 (2005).
3. Lubomirov R, di Iulio J, Fayet A et al. ADME pharmacogenetics: Investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet. Genomics 20(4), 217-230 (2010).
4. Kim KA, Park PW, Hong SJ, Park J-Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther. 84(2), 236-242 (2008
5. Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 10(1), 1-11 (2010).
6. Szakács G, Váradi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today. 13(9-10), 379-393 (2008).
7. Table of Pharmacogenomic Biomarkers in Drug Labeling. www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm
8. Roses AD. Pharmacogenetics and drug development: The path to safer and more effective drugs. Nat. Rev. Genet. 5(9), 645-656 (2004).
9. Roses AD. Pharmacogenetics in drug discovery and development: A translational perspective. Nat. Rev. Drug Discov. 7(10), 807-817 (2008).
10. Collet J-P, Hulot J-S, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 373(9660), 309-317 (2009).
11. Giusti B, Gori AM, Marcucci R et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am. J. Cardiol. 103(6), 806-811 (2009).
12. Mega JL, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19), 2553-2560 (2009).
13. Sibbing D, Stegherr J, Latz W et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur. Heart J. 30(8), 916-922 (2009).
14. Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360(4), 363-375 (2009).
15. Ross CJD, Katzov-Eckert H, Dubé M-P et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41(12), 1345-1349 (2009).
16. Burmester JK, Sedova M, Shapero MH, Mansfield E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol. Biol. 632, 99-124 (2010).
17. Deeken J. The Affymetrix DMET platform and pharmacogenetics in drug development. Curr. Opin. Mol. Ther. 11(3), 260-268 (2009).
18. Sissung TM, English BC, Venzon D, Figg WD, Deeken JF. Clinical pharmacology and pharmacogenetics in a genomics era: The DMET platform. Pharmacogenomics 11(1), 89-103 (2010).
19. Cuyàs E, Olano-Martín E, Khymenets O et al. Errors and reproducibility of DNA array-based detection of allelic variants in ADME genes: PHARMAchip. Pharmacogenomics 11(2), 257-266 (2010).
20. Jain KK. Applications of AmpliChip CYP450. Mol. Diagn. 9(3), 119-127 (2005).
21. VeraCode ADME Core Panel. http://res.illumina.com/documents/products/ datasheets/datasheet-veracode-Adme-core-panel.pdf
22. iPLEX̊ ADME PGx Panel. http://bioscience.sequenom. com/iplex-Adme-pgx-panel
23. Peiffer DA, Gunderson KL. Design of tag SNP whole genome genotyping arrays. Methods Mol. Biol. 529, 51-61 (2009).
24. PharmaADME. www.pharmaADME.org
25. International HapMap Consortium, Frazer KA, Ballinger DG et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 449(7164), 851-861 (2007).
26. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet. 74(1), 106-120 (2004).
27. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. www.cypalleles.ki.se/
28. Coriell Institute for Medical Research. www.coriell.org
29. Schroder A, Klein K, Winter S et al. Genomics of ADME gene expression: Mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver. Pharmacogenomics J. 13(1), 12-20 (2013).
30. De Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat. Genet. 37(11), 1217-1223 (2005).
31. Visscher H, Ross CJ, Dubé M-P et al. Application of principal component analysis to pharmacogenomic studies in Canada. Pharmacogenomics J. 9(6), 362-372 (2009).
32. Visscher H, Ross CJ, Rassekh SR et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol. 30(13), 1422-1428 (2012